3. As of noon trading, Biogen Idec ( BIIB) is down $1.67 (-0.7%) to $225.46 on average volume Thus far, 648,630 shares of Biogen Idec exchanged hands as compared to its average daily volume of 1.4 million shares. The stock has ranged in price between $223.11-$227.64 after having opened the day at $226.68 as compared to the previous trading day's close of $227.13.

Biogen Idec Inc. discovers, develops, manufactures, and markets therapies for the treatment of neurodegenerative diseases, hemophilia, and autoimmune disorders in the United States and internationally. Biogen Idec has a market cap of $54.6 billion and is part of the drugs industry. The company has a P/E ratio of 36.5, above the S&P 500 P/E ratio of 17.7. Shares are up 57.0% year to date as of the close of trading on Wednesday.

TheStreet Ratings rates Biogen Idec as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, impressive record of earnings per share growth, compelling growth in net income and expanding profit margins. We feel these strengths outweigh the fact that the company shows weak operating cash flow. Get the full Biogen Idec Ratings Report now.

Exclusive Offer: Jim Cramer's 'go-to' small/mid-cap guru Bryan Ashenberg only buys stocks he thinks could return 50-100%. See his top picks for 14-days FREE.

If you liked this article you might like

Elizabeth Warren Slams Wells Fargo, Equifax: Cramer's Top Takeaways

Centene: Cramer's Top Takeaways

The Pitney Bowes Transformation: Cramer's Top Takeaways

Healthcare Trust of America, Marathon Petroleum: 'Mad Money' Lightning Round

How Long Can This Rally Run?: Cramer's 'Mad Money' Recap (Monday 9/19/17)